Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Presentations
    • Overview
    • Press Releases
    • IR Calendar
    • Safe Harbor Statement
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Management Team
    • Contacts
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Presentations
  • Overview
  • Press Releases
  • IR Calendar
  • Safe Harbor Statement
  • Email Alerts

Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Jun 7, 2023

Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice

Jun 2, 2023

Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down

Jun 1, 2023

Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market

May 22, 2023

Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer

May 11, 2023

Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications

May 8, 2023

Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit

Apr 27, 2023

Navidea Biopharmaceuticals, Inc. Enters Asset Purchase Agreement with Meilleur Technologies, Inc. for Rights to NAV4694

Apr 13, 2023

Navidea Biopharmaceuticals, Inc. Hires G2G Ventures as Executive Consultants; Chief Medical Officer Steps Down

Mar 30, 2023

Navidea Biopharmaceuticals Reports Fourth Quarter 2022 Financial Results

Mar 21, 2023
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...44
© 2023 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
linkedin
Privacy Policy Disclaimer Sitemap